Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $55 from $50 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Promising Growth and Strategic Positioning Make Mirum Pharmaceuticals a Compelling Buy
- Mirum Pharmaceuticals: Strong Financial Performance and Strategic Advancements Drive Buy Rating
- Mirum Pharmaceuticals Reports Strong 2024 Growth
- Mirum Pharmaceuticals reports FY24 EPS ($1.85), consensus ($1.42)